MRUS - צמיחת הכנסות ב-12 חודשים נגררים Merus N.V.

Merus N.V. (MRUS) bets on innovative Biclonics antibodies to drive management's confidence in achieving its goals, as reflected in the TTM annual sales growth chart on the GURU.Markets platform, where 57.80 serves as the current parameter value. The efficiency model is completed by the full outsourcing of production and testing, which minimizes the company's capital expenditures.

The development of oncology drugs by Merus N.V. (MRUS) is complicated by geopolitical logistics disruptions and barriers to conducting international trials. This indicator calculates the percentage deviation of current revenue over the last 12 months compared to the same period last year. Growth in this metric confirms the fundamental resilience of the business, separating the long-term trend from short-term market volatility. By analyzing the annual change in TTM revenue, an investor assesses the real scalability of the company.